Hello, everyone, and how are you today? We are doing just fine, thank you, courtesy of a warm and shiny sun enveloping the Pharmalot campus. The short people have left for their destinations — the local schoolhouse and gainful employment, respectively — and the official mascot is snoozing in his corner. As for us, we are already quite busy firing up the coffee kettle and foraging for interesting items. Speaking of which, here are a few tidbits to get you going this morning. Hope your day burns brightly and, as always, do stay in touch …

Bristol-Myers Squibb (BMY) and Starboard Value issued dueling presentations over the merits of the $74 billion bid the drug maker has made for Celgene (CELG) (CELG). Bristol-Myers maintained that the deal would give the combined companies number-one positions in oncology and cardiovascular drug sales, while Starboard argued that Celgene is facing a “massive patent cliff” that will force it to replace about 60 percent of its revenues over the next seven years (here is the Bristol presentation and here is the Starboard presentation). Bristol shareholders vote on April 12.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy